Skip to main content
OpenTrials
Completed

NCT Number: NCT04344327

Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF

The COVID-19 pandemic of SARS CoV2 (Severe Acute Respiratory Syndrome, COVID-19) infection, which is currently evolving in France, raises many questions about the clinical and biological profile of infected hospitalized patients. If certain biological factors like troponin, BNP (Brain Natriuretic Peptid), or clinical factors like cardiovascular history or oncological history are associated with a worse prognosis, available data comes from studies in Asia for the majority, or including a limited number of patients. Patient stratification remains a major issue for patient sorting and early referral of patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infection Viral COVID Cross Infection Disease Attributes Iatrogenic Disease Infection, Hospital Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU d'Amiens, Amiens, France

Loading trial locations.

About this study

This study is observational, multicenter and retrospective, and is conducted in hospitals in France.

Clinical data relating to history, comorbidities, risk factors, previous treatments, treatments during the hospitalization and treatments at the discharge from hospital, clinical parameters, biological and ultrasound cardiological data, procedures and events during hospitalization will be recorded, in order to identify the early predictors of clinical worsening in patients hospitalized for COVID-19 in cardiology or conventional medicine department.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients hospitalized in cardiology unit or medicine conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)

Exclusion criteria

  • Minors
  • Pregnant women

Treatment and study plan

Primary outcomes

  1. Death rate

    Time frame: Through study completion, an average of 4 weeks

    Analysis of all-cause death in relation with clinical patient profile

  2. Transfer to intensive care unit

    Time frame: Through study completion, an average of 4 weeks

    Correlation between clinical patient profile and transfer need to intensive care unit

  3. Ventilation analysis

    Time frame: Through study completion, an average of 4 weeks

    Type of ventilation procedures needed during the hospitalization (Orotracheal intubation for mechanical ventilation or Non-invasive ventilation or 29/5000 high flow oxygen therapy - Optiflow) in relation with clinical patient profile

Secondary outcomes

  1. Construction of a predictive score for COVID-19 severe form

    Time frame: Through study completion, an average of 4 weeks

    Description of clinical and biological patient profile leading to a worse prognosis

Sponsors and collaborators

Lead sponsor

French Cardiology Society

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Acronym: CCF

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 14, 2020
Registry last updated
Apr 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.